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A AB BS ST TR RA AC CT T
B Ba ac ck kg gr ro ou un nd d: : This is a case of a solitary hepatic gastri-
noma in a 65-year-old male. The patient was diagnosed
with Zollinger-Ellison syndrome in 1991. He had nega-
tive radiologic and surgical explorations at that time. He
was maintained on proton-pump inhibitors for the next
10 years without symptoms.
M Me et th ho od ds s: : A computed tomographic (CT) scan done in
April 2001 demonstrated a 5-cm right hepatic lesion.
Radionucleotide scanning with octreotide demonstrated
intense activity in the same area in the right hepatic lobe.
His serum gastrin was 317 pg/mL. He underwent laparo-
scopic radiofrequency ablation of the lesion.
R Re es su ul lt ts s: :   Treatment resulted in a 6-cm ablative area giv-
ing a 1-cm margin on the tumor. One- and 3-month fol-
low-up CT scans demonstrated adequate ablation of the
tumor. An octreotide scan done 3 months postoperative-
ly did not reveal any areas of abnormal uptake.
C Co on nc cl lu us si io on n: : We report success with laparoscopic
radiofrequency ablation as an alternative to major hepat-
ic resection in patients with a solitary hepatic gastrinoma.
K Ke ey y    W Wo or rd ds s: : Laparoscopy, Radiofrequency ablation,
Hepatic gastrinoma.
I IN NT TR RO OD DU UC CT TI IO ON N
The annual incidence of the 2 most common neuroen-
docrine tumors, insulinoma and gastrinoma, is about 1
per million.1 Although insulinomas are usually benign,
60% to 80% of gastrinomas are malignant. Hepatic or
nodal metastases are found in 60% of patients diagnosed
with Zollinger-Ellison syndrome (ZES).2 Long-term (5-
year) survival of patients with resected extrahepatic gas-
trinoma is 95%.3 This number is decreased to 85% in
patients with resected hepatic metastases.4 However, 5-
year survival in patients with unresected hepatic gastri-
noma is a dismal 30%.2,5,6 Hepatic resection continues to
be an effective treatment for a solitary hepatic gastrino-
ma.2 Other methods have been tried in patients with
tumor locations or medical problems prohibiting major
hepatic resection. These include embolization,
chemoembolization, immunotherapy (interferon alpha),
liver transplantation, and chemotherapy. These methods
all have yielded unsatisfactory results with no reports of
complete remission.5,7-11 More recently, radiofrequency
ablation (RFA) has been used in cases of unresectable
hepatocellular or colorectal metastases.
Two large studies on RFA for primary hepatocellular and
colorectal metastases showed varied results. Curley et
al12 demonstrated a 1.8% recurrence at a mean follow-up
of 15 months in a series of 169 patients. Wood et al,13 in
a series of 231 patients, cited an 18% recurrence rate at
a mean follow-up of 9 months. No series has had effica-
cious RFAs in patients with hepatic gastrinoma. We
report a case of a 5-cm solitary hepatic gastrinoma treat-
ed with RFA with a resulting 1-cm margin on the tumor.
We propose RFA as an alternative to major hepatic resec-
tion in patients with solitary hepatic gastrinoma.
M ME ET TH HO OD DS S
Our patient is a 65-year-old male who was originally
treated at an outside hospital in 1988 for a perforated
gastric ulcer. This was repaired with a modified Graham
patch technique. He was then followed up with EGD
and treated medically for several recurrent ulcers. He
was referred to our institution in 1991 after a workup of
his ulcer disease led to a diagnosis of ZES. This diagno-
sis was based on elevated serum gastrin levels, a positive
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secretin stimulation test, and refractory ulcer disease. He
underwent several localizing studies including an abdom-
inal computed tomographic (CT) scan and radionu-
cleotide scanning with octreotide. The CT scan revealed
a 2-cm left adrenal nodule and no other masses. The
octreotide scan characterized the adrenal nodule as being
inactive. No other areas of activity were found on the
octreotide scan. At exploratory laparotomy, a thorough
examination, including the gastrinoma triangle, was car-
ried out. Several biopsies were taken from the following
locations: left lateral lobe of the liver, right lobe of the
liver (diaphragmatic surface), peri-portal lymph nodes,
and 2 anterior pancreatic nodules were shelled out. In
addition, an anterior duodenotomy was performed from
the pylorus through the third portion. Once again, no
tumor was identified. He has since been managed on
proton-pump inhibitors and routine medical follow-up,
including repeat CT scans.
In April 2001, a CT scan revealed a 5-cm mass in the right
lobe of the liver. In addition, the previous left adrenal
mass had increased to 5 cm. Octreotide scanning at this
time demonstrated intense activity in the right lobe of the
liver; however, the left adrenal nodule remained inactive.
Over the course of the past 10 years, the patient has
developed advanced emphysematous disease of the
lungs, gained 100 lbs, and developed type II diabetes.
The location of the tumor near major branches of the por-
tal vein would have necessitated a major right hepatic
lobectomy ( (F Fi ig gu ur re e   1 1) ). After discussion with the patient
and his family regarding his surgical options, the patient
was given the additional option of RFA via a laparoscop-
ic approach for his liver tumor. It was also recommend-
ed that he undergo a laparoscopic left adrenalectomy
due to the enlarging left adrenal nodule.
The patient underwent successful laparoscopic left
adrenalectomy and laparoscopic right hepatic tumor RFA.
We used the Aloka‚ reticulating laparoscopic ultrasound
to examine the liver and guide RFA probe placement.
The RITA model 1500 radiofrequency generator was used
in our patient at a frequency of 460 kHz. The ablation
device was the RITA‚ StarBurst XL (for 3- to 5-cm abla-
tion). The electrode was first deployed at the most pos-
terior interface, and then, after ablation, was subse-
quently withdrawn and redeployed at the most anterior
interface in the tumor to create overlapping zones of
necrosis ( (F Fi ig gu ur re e   2 2) ). Power delivery was set at 50 watts,
and the lesion was heated to a temperature of 90°C for
10 minutes. Upon withdrawing the electrode, the tem-
perature was maintained to ablate the tract of the needle.
R RE ES SU UL LT TS S   
The patient’s RFA was complicated by an intraoperative
right pneumothorax, believed to be caused by a punc-
ture to the diaphragm by the 25-gauge-seeker needle
used to locate the tumor. This was treated by placement
of a 22-French chest tube, which was removed on post-
F Fi ig gu ur re e   1 1. . CT scan of patient’s right hepatic tumor. F Fi ig gu ur re e   2 2. . Intraoperative ultrasound of tumor ablation.operative day 2. The patient was discharged home on
postoperative day 3 without any further sequelae.
Pathologic examination of the adrenal gland revealed a
4.5 x 5.1 x 4.5-cm adrenal cortical adenoma. The patient
was seen in the office 2 weeks postoperatively and was
doing well. His follow-up CT scan ( (F Fi ig gu ur re e   3 3) ) demon-
strated complete destruction of the lesion seen on the
preoperative CT scan with an apparent 1-cm additional
margin based on the increased size of the ablative lesion
to 6.0 cm x 6.0 cm x 5.1 cm. Postoperative blood work
revealed the following: gastrin 473 pg/mL, insulin 24
U/mL, serotonin 244 ng/mL, and pancreatic polypeptide
852 pg/mL. These hormones are sensitive markers for
hepatic gastrinoma and useful for monitoring tumor
recurrence.14
A second follow-up CT scan was done 3 months post-
operatively to reevaluate this lesion ( (F Fi ig gu ur re e    4 4) ). This
demonstrated a decrease in size of the ablated lesion,
and no evidence of new lesions. Repeat blood work at
this time revealed an elevated serum gastrin of 754
pg/mL. His serum pancreatic polypeptide and serotonin,
however, were decreased to 660 pg/mL and 161 ng/mL,
respectively. In light of this, a radionucleotide scan with
octreotide was performed. This revealed no areas of
abnormal uptake in the body. This patient will be fol-
lowed with octreotide scans and CT scans on a biannual
basis.
D DI IS SC CU US SS SI IO ON N   
Neuroendocrine tumors (NETs) typically arise from the
islet cells of Langerhans. NETs fall into 1 of 5 categories:
insulinoma, gastrinoma, glucagonoma, vipoma, and
somatostatinoma. The majority of primary gastrinomas
are found in the duodenum (40% to 50%), the head of
the pancreas (30% to 50%), and lymph nodes (17%) with-
in the gastrinoma triangle (defined by the junction of the
cystic duct with the common bile duct, junction of the
second and third portion of the duodenum, and the junc-
tion of the neck and the body of the pancreas). Ectopic
gastrinomas can be found in the stomach, parathyroids,
kidney, common bile duct, ovary, lymph nodes, and
liver. Patients with localized resectable liver metastases
from gastrinoma are rare.4 The presence of neuroen-
docrine cells in the normal bile duct explains the possi-
ble development of ectopic primary hepatic gastrino-
ma.15 Although a 20% correlation exists between ZES and
multiple endocrine neoplasia type 1 (MEN 1), no corre-
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lation appears to exist between primary hepatic gastrino-
ma and MEN 1, based on the cases reported in the liter-
ature.15
F Fi ig gu ur re e    3 3. . One month post-radiofrequency ablation CT scan
demonstrating ablated lesion.
F Fi ig gu ur re e   4 4. . Three month post-radiofrequency ablation CT scan
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Making a diagnosis of primary hepatic gastrinoma relies
on preoperative localizing studies and a thorough intra-
operative exploration to rule out an occult primary with
hepatic metastases. CT and magnetic resonance imaging
(MRI) are both of limited use. CT can miss smaller hepat-
ic lesions, with 1 study citing 63% sensitivity for gastrino-
ma.4 MRI was found to be more sensitive (78%) but can-
not distinguish between gastrinomas and small hepatic
hemangiomas.4 Recent studies have shown somatostatin
receptor scintigraphy (SRS) to have a sensitivity of 90%
with few false positives.4 Intraoperative ultrasound
(IOUS) is the most sensitive device for detection of hepat-
ic tumors. IOUS is even more sensitive than palpation,
which can miss some smaller lesions located deep in the
liver parenchyma.
Once the diagnosis of hepatic gastrinoma has been made,
the next step is treatment. Currently, surgery is the only
effective treatment for gastrinoma.3 For those patients
who are not candidates for surgical resection, other treat-
ment options must be explored. In 1 prospective ran-
domized study of 213 patients with ZES, only 17 (8%) had
localized liver gastrinoma and were candidates for surgi-
cal resection.4 One of the newest treatment alternatives
for unresectable liver tumors is RFA.12 This has been used
for treating primary hepatocellular carcinoma and hepat-
ic colorectal metastases that were unresectable secondary
to the number of lesions, anatomic location near main
portal vessels, or inability of the patient to tolerate major
hepatic resection.12
Radiofrequency ablation (RFA) is a thermal treatment
technique designed to produce localized tumor destruc-
tion by heating tumor tissue to temperatures that exceed
50°C. When tumor cells are heated to temperatures above
45° to 50°C for more than 3 minutes, intracellular protein
denaturation and melting of lipid bilayers results in direct
tumor cell death.16 RFA uses alternating currents passed
across needle electrode arrays placed directly into the
tumor. Ionic stimulation induced by the alternating cur-
rent in tissue surrounding the electrode array produces
gradual frictional heating, and the tissue temperatures rise
to 80° to 110°C, which results in coagulative necrosis of
the tissue in proximity to the electrode. The basic princi-
ple is similar to that of the surgical electrocautery units
used to achieve intraoperative hemostasis.17
Novel RF needle designs have been developed with mul-
tiple-array hook electrodes that are deployed from the
needle tip into the tumor.12 The insulated 14- to 18-gauge
needle electrode shaft is placed into the tumor with the
multiple-hook array retracted. Using real-time ultrasono-
graphic guidance, the array is deployed from the needle
tip into the tumor. The multiple-array hook electrodes
are available in maximum diameters of 2.0 to 5.0 cm. In
contrast to the small areas of tumor tissue ablation creat-
ed by simple needle electrodes, multiple-array elec-
trodes, such as the LeVeen electrode, can produce zones
of coagulative necrosis 2.0 to 6.0 cm in diameter.17 For
tumors less than 2.5 cm in diameter, the multiple arrays
are deployed into the center of the tumor. For larger
lesions, the array is first deployed at the most posterior
interface (ultrasonographically) between tumor and nor-
mal liver parenchyma; it is subsequently withdrawn and
redeployed at 2.0- to 2.5-cm intervals in the tumor.
Optimal positioning of the electrode permits complete
destruction of the tumor and at least a 1-cm zone of nor-
mal liver parenchyma.17
In our case, we describe a successful laparoscopic RFA
of a 5-cm hepatic gastrinoma with a 1-cm margin. The
patient was discharged from the hospital on postopera-
tive day number 3, and avoided major hepatic resection.
As had been previously demonstrated, intraoperative
ultrasound provides better resolution of the tumor for
RFA treatment compared with transabdominal ultrasound
or CT for percutaneous treatment.18 Incomplete tumor
destruction has been reported in up to 18% of liver can-
cers treated percutaneously with RFA.18 This underscores
both the importance of careful treatment planning to
overlap the zones of necrosis and the need for early
post-RFA, CT, or MRI to detect incompletely treated
tumors after percutaneous RFA.18
C CO ON NC CL LU US SI IO ON N
No studies exist at this time documenting long-term fol-
low-up of patients with hepatic gastrinoma treated with
RFA. In our case, we achieved satisfactory immediate
results based on postoperative CT showing adequate
ablation of the tumor with a 1-cm margin. These results
were supported by 3-month follow-up studies including
a CT scan and an octreotide scan, both showing evi-
dence of adequate ablation of the tumor. Concern still
exists about the presence of an unidentified gastrinoma
primary as is evidenced by the patient’s persistent ele-
vated serum gastrin. The slow-growing nature of this
tumor, however, will make radiologic surveillance for
treatable disease possible. Although surgical resectionremains the gold standard for treatment of hepatic gas-
trinomas, RFA may be a promising alternative for those
patients in whom hepatic resection is not possible. 
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